Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Apr 10;7(6):1770-1780.
doi: 10.7150/thno.18421. eCollection 2017.

Diagnostic Accuracy of Ga-68-HBED-CC-PSMA-Ligand-PET/CT before Salvage Lymph Node Dissection for Recurrent Prostate Cancer

Affiliations

Diagnostic Accuracy of Ga-68-HBED-CC-PSMA-Ligand-PET/CT before Salvage Lymph Node Dissection for Recurrent Prostate Cancer

Cordula A Jilg et al. Theranostics. .

Abstract

Background: By targeting the prostate-specific membrane antigen (PSMA) on prostate cancer (PCa) cells PSMA-PET/CT shows great potential in locating the site of biochemical recurrence even at low PSA (Prostate-specific antigen)-levels. Accurate imaging of PCa recurrent lymph node metastases (LNM) is crucial for metastases directed therapies such as salvage-lymph node dissection (salvage-LND). Objective: To evaluate the diagnostic accuracy of PSMA-PET/CT for detection of affected lymph-node regions at salvage-LND for nodal recurrence of PCa. Design, setting and participants: 30 patients with the suspicion of exclusively nodal PCa-relapse after primary therapy underwent a template pelvic and/or retroperitoneal salvage-LND after whole body 68-Ga-PSMA-PET/CT. The diagnostic accuracy of PET/CT was evaluated in comparison to the histopathology of 965 resected lymph nodes (LN) dissected from 68 main regions (pelvic left/right, retroperitoneal) and 289 subregions (common iliac, external iliac, obturator, internal iliac, presacral, aortic-bifurcation, aortal, caval). LNM and tumor deposits in LNM were measured bidimensionally in the histopathology. PSMA-expression was analyzed by immunohistochemistry in LNM. Results: LNM were present in 11.4% of the resected LN (110/965) resulting in 45 positive main regions and 85 positive subregions. PET/CT was true positive in 41 main regions and 69 subregions. Three PET-negative main regions and 16 PET-negative subregions finally contained LNM, the majority of these false negative subregions (13/16) were in neighboring regions of true-positive subregions. Sensitivity, specificity, positive predictive value, negative predictive value and accuracy were: main region-based 93.2%, 100%, 100%, 88.9% and 95.6%, subregion-based 81.2%, 99.5%, 98.6%, 92.7 and 94.1%. Median short diameters of tumor deposits in LNM resected from false-negative subregions (1.3 mm) were significantly smaller than in LNM removed from true-positive subregions (5.5 mm, p<0.0001). Based on anatomical subregions containing just one LNM, the necessary short diameter of tumor deposits in LNM required to reach a detection rate of 50% and 90% was estimated to be ≥ 2.3 mm and ≥ 4.5 mm, respectively. Conclusion: In men with biochemical PCa-relapse and positive PSMA-PET/CT, PET/CT detects metastatic affected anatomical regions with high accuracy at a main region and at a subregion-level. If the decision for salvage-LND is prompted by a positive PSMA-PET/CT, the size of metastases is crucial for accurate detection of affected regions. All LNM showed a clear PSMA-expression in the immunohistochemistry. Further studies need to investigate how to translate the high anatomical correlation observed between PET/CT and surgical findings into optimal approaches for target salvage-LND.

Keywords: PSMA-PET/CT; prostate cancer, lymph node metastases; salvage lymph node dissection; salvage lymphadenectomy..

PubMed Disclaimer

Conflict of interest statement

Competing Interests: PTM received financial support for on-going research by GE and Piramal Imaging unrelated to the present study. CAJ, VD, TB, KS, WSS, UW, HCR, WV have no financial disclosures.

Figures

Figure 1
Figure 1
(A, B) Maximum intensity projections (MIP) of PSMA-PET/CT and the transversal PET (E, F) with the corresponding CT (C, D) images from patient N°1 with a single lymph node metastasis (initial PSA 7.43 ng/ml, Gleason-score 3+4 at radical prostatectomy in history, PSA 1.72 ng/ml at salvage-lymphadenectomy) and patient N°2 with multiple lymph node metastases (initial PSA 4.11 ng/ml, Gleason-score 4+5 at radical prostatectomy in history, PSA 1.78 ng/ml at salvage-lymphadenectomy). Red arrows indicate lymph node metastases.
Figure 2
Figure 2
Boxplots showing the sizes of whole lymph node metastases (A) and tumor deposits in lymph nodes (B) either removed from true-positive or false-negative subregions at surgery. Sizes are shown in two dimensions: median longitudinal and short-axis diameters (mm) of (A) lymph node metastases and (B) tumor deposits in lymph node metastases. Thick horizontal lines represent medians, crosses represent means, boxes show the 25th and 75th percentiles, whiskers represent the minimum and maximum values. n.s. p > 0.05, ** p ≤ 0.01, *** p ≤ 0.001. (C) Detection rates of LNMs in dependence on the longitudinal diameter of tumor deposits in lymph node metastases (LNM). The estimated threshold to reach a detection rate of 90% (d90) is 6.0 mm. (D) Detection rates of LNMs in dependence on the short axis diameters of tumor deposits in lymph node metastases (LNM). The estimated threshold to reach a detection rate of 90% (d90) is 4.5 mm.
Figure 2
Figure 2
Boxplots showing the sizes of whole lymph node metastases (A) and tumor deposits in lymph nodes (B) either removed from true-positive or false-negative subregions at surgery. Sizes are shown in two dimensions: median longitudinal and short-axis diameters (mm) of (A) lymph node metastases and (B) tumor deposits in lymph node metastases. Thick horizontal lines represent medians, crosses represent means, boxes show the 25th and 75th percentiles, whiskers represent the minimum and maximum values. n.s. p > 0.05, ** p ≤ 0.01, *** p ≤ 0.001. (C) Detection rates of LNMs in dependence on the longitudinal diameter of tumor deposits in lymph node metastases (LNM). The estimated threshold to reach a detection rate of 90% (d90) is 6.0 mm. (D) Detection rates of LNMs in dependence on the short axis diameters of tumor deposits in lymph node metastases (LNM). The estimated threshold to reach a detection rate of 90% (d90) is 4.5 mm.
Figure 2
Figure 2
Boxplots showing the sizes of whole lymph node metastases (A) and tumor deposits in lymph nodes (B) either removed from true-positive or false-negative subregions at surgery. Sizes are shown in two dimensions: median longitudinal and short-axis diameters (mm) of (A) lymph node metastases and (B) tumor deposits in lymph node metastases. Thick horizontal lines represent medians, crosses represent means, boxes show the 25th and 75th percentiles, whiskers represent the minimum and maximum values. n.s. p > 0.05, ** p ≤ 0.01, *** p ≤ 0.001. (C) Detection rates of LNMs in dependence on the longitudinal diameter of tumor deposits in lymph node metastases (LNM). The estimated threshold to reach a detection rate of 90% (d90) is 6.0 mm. (D) Detection rates of LNMs in dependence on the short axis diameters of tumor deposits in lymph node metastases (LNM). The estimated threshold to reach a detection rate of 90% (d90) is 4.5 mm.
Figure 3
Figure 3
(A) Representative immunohistochemistry (IHC) for prostate-specific membrane antigen (PSMA) in lymph node metastases removed from a true-positive subregions (dark brown). (B) IHC for PSMA in small tumor deposits in lymph node metastases removed from false-negative subregions.

Comment in

Similar articles

Cited by

References

    1. Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T. et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. European urology. 2014;65:467–79. - PubMed
    1. Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T. et al. EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. European urology. 2014;65:124–37. - PubMed
    1. Picchio M, Briganti A, Fanti S, Heidenreich A, Krause BJ, Messa C. et al. The role of choline positron emission tomography/computed tomography in the management of patients with prostate-specific antigen progression after radical treatment of prostate cancer. European urology. 2011;59:51–60. - PubMed
    1. Jilg CA, Schultze-Seemann W, Drendel V, Vach W, Wieser G, Krauss T, Detection of Lymph Node Metastasis in Patients with Nodal Prostate Cancer Relapse Using F/C-Choline Positron Emission Tomography/Computerized Tomography. The Journal of urology; 2014. - PubMed
    1. Cimitan M, Evangelista L, Hodolic M, Mariani G, Baseric T, Bodanza V. et al. Gleason score at diagnosis predicts the rate of detection of 18F-choline PET/CT performed when biochemical evidence indicates recurrence of prostate cancer: experience with 1,000 patients. J Nucl Med. 2015;56:209–15. - PubMed

Publication types

MeSH terms

Substances